|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Daniels MG, Bowman RV, Yang IA, Govindan R
and Fong KM: An emerging place for lung cancer genomics in 2013. J
Thorac Dis. 5 (Suppl 5):S491–S497. 2013.PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Askoxylakis V, Thieke C, Pleger ST, Most
P, Tanner J, Lindel K, Katus HA, Debus J and Bischof M: Long-term
survival of cancer patients compared to heart failure and stroke: A
systematic review. BMC Cancer. 10:1052010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saito S, Espinoza-Mercado F, Liu H, Sata
N, Cui X and Soukiasian HJ: Current status of research and
treatment for non-small cell lung cancer in never-smoking females.
Cancer Biol Ther. 18:359–368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zarogoulidis K, Zarogoulidis P, Darwiche
K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N,
Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of
non-small cell lung cancer (NSCLC). J Thorac Dis. 4 (Suppl
5):S389–S396. 2013.
|
|
7
|
Farhat FS and Houhou W: Targeted therapies
in non-small cell lung carcinoma: What have we achieved so far?
Ther Adv Med Oncol. 5:249–270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pirozynski M: 100 years of lung cancer.
Respir Med. 100:2073–2084. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwartz AG, Prysak GM, Bock CH and Cote
ML: The molecular epidemiology of lung cancer. Carcinogenesis.
28:507–518. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spiro SG and Silvestri GA: One hundred
years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blandin Knight S, Crosbie PA, Balata H,
Chudziak J, Hussell T and Dive C: Progress and prospects of early
detection in lung cancer. Open Boil. 7:1700702017. View Article : Google Scholar
|
|
12
|
Vilmar AC and Sorensen JB: Customising
chemotherapy in advanced nonsmall cell lung cancer: Daily practice
and perspectives. Eur Respir Rev. 20:45–52. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang T, Nelson RA, Bogardus A and Grannis
FW Jr: Five-year lung cancer survival: Which advanced stage
nonsmall cell lung cancer patients attain long-term survival?
Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Feng QQ, Gong JH and Ma JP:
Anticancer effects of isofraxidin against A549 human lung cancer
cells via the EGFR signaling pathway. Mol Med Rep. 18:407–414.
2018.PubMed/NCBI
|
|
15
|
Bailey SM, Meyne J, Chen DJ, Kurimasa A,
Li GC, Lehnert BE and Goodwin EH: DNA double-strand break repair
proteins are required to cap the ends of mammalian chromosomes.
Proc Natl Acad Sci USA. 96:14899–14904. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vazquez A, Bond EE, Levine AJ and Bond GL:
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat
Rev Drug Discov. 7:979–987. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Choisy-Rossi C, Reisdorf P and
Yonish-Rouach E: Mechanisms of p53-induced apoptosis: In search of
genes which are regulated during p53-mediated cell death. Toxicol
Lett. 102-103:491–496. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bunz F, Dutriaux A, Lengauer C, Waldman T,
Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B:
Requirement for p53 and p21 to sustain G2 arrest after
DNA damage. Science. 282:1497–1501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pietenpol JA and Stewart ZA: Cell cycle
checkpoint signaling: Cell cycle arrest versus apoptosis.
Toxicology. 181-182:475–481. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pflaum J, Schlosser S and Muller M: p53
family and cellular stress responses in cancer. Front Oncol.
4:2852014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi Y: Mechanisms of caspase activation
and inhibition during apoptosis. Mol Cell. 9:459–470. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yunlan L, Juan Z and Qingshan L: Antitumor
activity of di-n-
butyl-(2,6-difluorobenzohydroxamato)tin(IV) against human gastric
carcinoma SGC-7901 cells via G2/M cell cycle arrest and cell
apoptosis. PLoS One. 9:e907932014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang Z, Fu J and Zhang Y: Nitric oxide
donor-based cancer therapy: Advances and prospects. J Med Chem.
60:7617–7635. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Laschak M, Spindler KD, Schrader AJ,
Hessenauer A, Streicher W, Schrader M and Cronauer MV: JS-K, a
glutathione/glutathione S-transferase-activated nitric oxide
releasing prodrug inhibits androgen receptor and WNT-signaling in
prostate cancer cells. BMC Cancer. 12:1302012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu L, Huang Z, Chen J, Wang J and Wang S:
Protein phosphatase 2A mediates JS-K-induced apoptosis by affecting
Bcl-2 family proteins in human hepatocellular carcinoma HepG2
cells. J Cell Biochem. 119:6633–6643. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shami PJ, Saavedra JE, Wang LY, Bonifant
CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, et al:
JS-K, a glutathione/glutathione S-transferase-activated nitric
oxide donor of the diazeniumdiolate class with potent
antineoplastic activity. Mol Cancer Ther. 2:409–417.
2003.PubMed/NCBI
|
|
28
|
Kiziltepe T, Hideshima T, Ishitsuka K,
Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, et
al: JS-K, a GST-activated nitric oxide generator, induces DNA
double-strand breaks, activates DNA damage response pathways, and
induces apoptosis in vitro and in vivo in human multiple myeloma
cells. Blood. 110:709–718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qiu M, Chen L, Tan G, Ke L, Zhang S, Chen
H and Liu J: A reactive oxygen species activation mechanism
contributes to JS-K-induced apoptosis in human bladder cancer
cells. Sci Rep. 5:151042015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qiu M, Ke L, Zhang S, Zeng X, Fang Z and
Liu J: JS-K, a GST-activated nitric oxide donor prodrug, enhances
chemo- sensitivity in renal carcinoma cells and prevents cardiac
myocytes toxicity induced by Doxorubicin. Cancer Chemother
Pharmacol. 80:275–286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Simeone AM, McMurtry V, Nieves-Alicea R,
Saavedra JE, Keefer LK, Johnson MM and Tari AM: TIMP-2 mediates the
anti-invasive effects of the nitric oxide-releasing prodrug JS-K in
breast cancer cells. Breast Cancer Res. 10:R442008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maciag AE, Chakrapani H, Saavedra JE,
Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM and Keefer
LK: The nitric oxide prodrug JS-K is effective against
non-small-cell lung cancer cells in vitro and in vivo: Involvement
of reactive oxygen species. J Pharmacol Exp Ther. 336:313–320.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ou X, Lu Y, Liao L, Li D, Liu L, Liu H and
Xu H: Nitidine chloride induces apoptosis in human hepatocellular
carcinoma cells through a pathway involving p53, p21, Bax and
Bcl-2. Oncol Rep. 33:1264–1274. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shin SY, Yong Y, Kim CG, Lee YH and Lim Y:
Deoxypodophyllotoxin induces G2/M cell cycle arrest and
apoptosis in HeLa cells. Cancer Lett. 287:231–239. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hwang HJ, Kang YJ, Hossain MA, Kim DH,
Jang JY, Lee SH, Yoon JH, Moon HR, Kim HS, Chung HY, et al: Novel
dihydrobenzofuro[4,5-b][1,8]naphthyridin-6-one derivative, MHY-449,
induces apoptosis and cell cycle arrest in HCT116 human colon
cancer cells. Int J Oncol. 41:2057–2064. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Muller-Tidow C, Metzger R, Kugler K,
Diederichs S, Idos G, Thomas M, Dockhorn-Dworniczak B, Schneider
PM, Koeffler HP, Berdel WE, et al: Cyclin E is the only
cyclin-dependent kinase 2-associated cyclin that predicts
metastasis and survival in early stage non-small cell lung cancer.
Cancer Res. 61:647–653. 2001.PubMed/NCBI
|
|
37
|
Bulavin DV, Higashimoto Y, Popoff IJ,
Gaarde WA, Basrur V, Potapova O, Appella E and Fornace AJ Jr:
Initiation of a G2/M checkpoint after ultraviolet radiation
requires p38 kinase. Nature. 411:102–107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen YL, Lin SZ, Chang JY, Cheng YL, Tsai
NM, Chen SP, Chang WL and Harn HJ: In vitro and in vivo studies of
a novel potential anticancer agent of isochaihulactone on human
lung cancer A549 cells. Biochem Pharmacol. 72:308–319. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lew DJ and Kornbluth S: Regulatory roles
of cyclin dependent kinase phosphorylation in cell cycle control.
Curr Opin Cell Biol. 8:795–804. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K
and Linn S: Molecular mechanisms of mammalian DNA repair and the
DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Srivastava RK, Chen Q, Siddiqui I, Sarva K
and Shankar S: Linkage of curcumin-induced cell cycle arrest and
apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1).
Cell Cycle. 6:2953–2961. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Migita T, Oda Y, Naito S and Tsuneyoshi M:
Low expression of p27Kip1 is associated with tumor size
and poor prognosis in patients with renal cell carcinoma. Cancer.
94:973–979. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
O'Connell MJ, Walworth NC and Carr AM: The
G2-phase DNA-damage checkpoint. Trends Cell Biol. 10:296–303. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chaudhary P, Sharma R, Sahu M, Vishwanatha
JK, Awasthi S and Awasthi YC: 4-Hydroxynonenal induces
G2/M phase cell cycle arrest by activation of the ataxia
telangiectasia mutated and Rad3-related protein (ATR)/checkpoint
kinase 1 (Chk1) signaling pathway. J Biol Chem. 288:20532–20546.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guicciardi ME, Malhi H, Mott JL and Gores
GJ: Apoptosis and necrosis in the liver. Compr Physiol. 3:977–1010.
2013.PubMed/NCBI
|
|
46
|
Zhu X, Wang K, Zhang K, Zhang T, Yin Y and
Xu F: Ziyuglycoside I inhibits the proliferation of MDA-MB-231
breast carcinoma cells through inducing p53-mediated G2/M cell
cycle arrest and intrinsic/extrinsic apoptosis. Int J Mol Sci.
17:E19032016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
McIlwain DR, Berger T and Mak TW: Caspase
functions in cell death and disease. Cold Spring Harb Perspect
Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT,
Liu B and Bao JK: Programmed cell death pathways in cancer: A
review of apoptosis, autophagy and programmed necrosis. Cell
Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang Q, Ma S, Liu B, Liu J, Zhu R and Li
M: Chrysin induces cell apoptosis via activation of the
p53/Bcl-2/caspase-9 pathway in hepatocellular carcinoma cells. Exp
Ther Med. 12:469–474. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Brady CA, Jiang D, Mello SS, Johnson TM,
Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ,
McLaughlin ME, et al: Distinct p53 transcriptional programs dictate
acute DNA-damage responses and tumor suppression. Cell.
145:571–583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Burmakin M, Shi Y, Hedstrom E, Kogner P
and Selivanova G: Dual targeting of wild-type and mutant p53 by
small molecule RITA results in the inhibition of N-Myc and key
survival oncogenes and kills neuroblastoma cells in vivo and in
vitro. Clin Cancer Res. 19:5092–5103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zeng G, Liu J, Chen H, Liu B, Zhang Q, Li
M and Zhu R: Dihydromyricetin induces cell cycle arrest and
apoptosis in melanoma SK-MEL-28 cells. Oncol Rep. 31:2713–2719.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Reed JC: Bcl-2 family proteins: Regulators
of apoptosis and chemoresistance in hematologic malignancies. Semin
Hematol 34 (4 Suppl 5). S9–S19. 1997.
|
|
54
|
Pettersson F, Dalgleish AG, Bissonnette RP
and Colston KW: Retinoids cause apoptosis in pancreatic cancer
cells via activation of RAR-gamma and altered expression of
Bcl-2/Bax. Br J Cancer. 87:555–561. 2002. View Article : Google Scholar : PubMed/NCBI
|
